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Although the transmission of blood-borne viral infections such as HIV and hepatitis C virus among 
people who inject drugs has garnered substantial attention, there has been less focus on other 
injecting-related injuries and diseases (IRID) in this population. These commonly include soft tissue 
infections such as abscesses and cellulitis, which occur as a result of micro-organisms (i.e. bacteria 
and fungi) in the injecting environment. Other infections may include bone and joint infections, 
infective endocarditis, and sepsis; these can arise as a result of direct introduction of bacteria to the 
bloodstream, or as complications of untreated of soft tissue infections.1  
In addition to infections, repeated injecting and poor injecting technique may lead to vascular injury 
and poor venous access; furthermore, drug solutions may contain inactive ingredients that are not 
water soluble, leading to particles in the vasculature that can cause  inflammation and formations of 
clots.2, 3 The likelihood of vascular injury can be further exacerbated by the delivery method (e.g., 
intravenous versus intramuscular injection), injecting site (e.g., subcutaneous tissue and muscle, 
major vessels), and type of equipment used.4   
Some IRID necessitate urgent medical care, and all can result in poorer health outcomes for people 
who inject drugs, including risk of mortality, if untreated.5 From an economic perspective, the costs 
of hospital care for IRID can be substantial.6, 7 A clearer understanding of the prevalence of IRID is 
needed to determine the scale of the problem and guide the development of evidence-informed 
responses. This review aimed to assess prevalence of non-viral IRID among people who inject drugs.  
 
  
  
Method 
This review is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) checklist.8 
Search strategy and study selection 
We searched MEDLINE, Embase and CINAHL for relevant literature using search strings developed in 
consultation with a specialist drug and alcohol librarian (see supplementary materials). Searches 
were undertaken in February 2014 and updated in July 2015. Search results were catalogued using 
Endnote X6. Titles and abstracts were independently screened by SL and a research assistant to 
produce a shortlist of potentially relevant reports. The full text of each shortlisted report was 
retrieved and read to determine eligibility for inclusion in the review. For articles in languages other 
than English, eligibility for the review was determined based on information available in English 
translations of abstracts.  
Reports were eligible for inclusion in the study if they included data on the prevalence of, or risk 
factors for, any non-viral IRID in a sample of people who injected illicit drugs. Reports could include 
data on any IRID, but data were required to be specific to a named infection, injury or disease, rather 
than a combination of different types of IRID. Where there was clearly overlap between reports in 
terms of the study sample (e.g. multiple reports from one study, sometimes using sub-samples of a 
larger sample) and types of IRID reported, we included only the study with the largest sample size. If 
multiple reports from the same study reported the same IRID over different prevalence periods, all 
reports were included.   
Articles that reported on specific sub-groups of people who inject drugs, such as HIV-infected 
injectors, or groin injectors, were excluded. Reports based on samples of people who exclusively 
injected performance and image-enhancing drugs were excluded, as this group is distinct from 
people who inject illicit drugs in terms of frequency of injecting, intravenous versus intramuscular 
  
injecting, and the environmental and social contexts of injecting. Reports that included data on 
pathology within people who inject drugs, that was not directly linked to injecting, were excluded.  
Data extraction 
Data were independently extracted by SL and a research assistant, with discrepancies resolved 
through discussion and consultation with BM. Data extracted from each article included sampling 
approach; demographic characteristics of the sample; types of IRID assessed; whether IRID 
ascertainment was based on self-report, clinical examination, or medical records; denominator and 
numerator for each IRID reported; and measures of association between IRID and other factors. 
Risk of bias assessment 
There is no ‘gold standard’ for the assessment of risk of bias in systematic reviews of epidemiological 
or observational studies. We considered two existing tools, one designed for use with population-
based epidemiological surveys,9 and the other for assessing HIV prevalence and risk in convenience 
samples of men who have sex with men.10 These were adapted to produce a five-item risk of bias 
tool. This assessed sampling approach; response rate; whether data were based on self-report or 
clinical examination/medical records; in the case of self-reported data, whether steps were taken to 
increase the validity of self-reports (e.g. providing participants with a definition of the IRID in 
question; symptom checklists); and completeness of reporting (i.e. all numerators and denominators 
reported). The findings of the risk of bias assessment informed interpretation of the quantitative 
data and meta-analyses. 
Data synthesis and analysis 
The various IRID that were identified through the literature search were categorised post hoc into 
the following categories: skin infections at injection sites (e.g. abscess, cellulitis); infective 
endocarditis; sepsis/septicaemia; bone and joint infections (e.g. osteomyelitis, septic arthritis); other 
infections; thrombosis and emboli; and other pathology and dysfunction associated with injecting 
  
drug use. Given wide variation between studies in reported prevalence estimates, data were not 
synthesised. Results for each study are presented graphically, by prevalence period.   
We had planned to do stratified meta-analyses by sex, age, duration of injecting, injection frequency, 
primary drug injected, and engagement in harm reduction strategies (i.e., opioid substitution 
treatment (OST); needle and syringe programs (NSPs); and supervised injecting facilities) in order to 
identify potential risk and protective factors for IRID.  However, many studies did not report the 
necessary data (i.e. insufficient information on group numerators and denominators), or only that 
there was a lack of a statistically significant association between the variable and outcome (without 
an odds ratio or numerators/denominators). Consequently a narrative review is presented for each 
IRID where data were available in reference to the selected risk/protective factors.  
  
  
Results 
The literature searches returned 3,578 unique records. Of these, 3,254 were deleted following 
screening of titles and abstracts, leaving 324 reports to be reviewed in full. Thirty-two reports met 
the inclusion criteria; 29 reports provided data on IRID prevalence, and 16 provided data on IRID risk 
factors (Figure 1). Included studies were largely from high-income countries, and participants were 
typically recruited from needle and syringe programs and drug treatment clinics. The IRID most 
frequently included in reports was skin infections (Table 1). 
***Figure 1 approximately here*** 
***Table 1 approximately here*** 
Skin infections at injecting sites 
Twenty-two reports presented data on the prevalence of skin infections at injecting sites (Figure 2 
and Supplementary Table 2). Terminology for skin infections varied across reports. The majority 
referred specifically to abscesses, but some used terms such as “injection site infection”.   
Seven reports provided estimates of current/past month abscess prevalence, which ranged between 
6.1% (95% CI: 4.6%, 7.9%) and 32.0% (25.0-39.6%); four of these included a physical examination to 
confirm the presence of infection (prevalence estimates in these studies ranged from 10.0-32.0%). 
Eleven reports provided estimates of 6-12 month prevalence, which ranged between 6.9% (4.6-
9.8%) and 37.3% (34.1-40.6%); and 12 reports estimates of lifetime prevalence, which ranged 
between 6.2% (5.8-6.7%) and 68.6% (56.4-79.1%) (Figure 2).  
***Figure 2 approximately here*** 
Women generally had greater odds than men of skin infections at injecting sites, with six studies 
finding this association, although three additional studies showed no statistically significant 
association (two following adjustment for confounders) (Table 2). Seven of eleven studies showed 
no significant association between age and current/past 6-12 month skin infection; the remaining 
  
studies reported greater odds of skin infection with older age (typically ≥30 years). Of seven studies 
examining duration of injecting, two had insufficient evidence of an association with skin infections; 
four reported greater risk of skin infection with increasing duration of injecting; and one reported 
only p<.001, without indicating the direction of the association. The literature was divided in regards 
to frequency of injection as a risk factor for skin infection (Table 2). Only one study directly 
compared injectors of specific drug types; compared to people who injected only opioids in the past 
year, people who had injected only stimulants had lower odds (OR 0.49; 95% CI: 0.34, 0.71), and 
people who had injected both opioids and stimulants had greater odds (OR 1.24, 95% CI: 1.09, 1.40) 
of past 12-month skin infections at injecting sites (data not shown).11  
While there was no significant association between always injecting in a supervised injecting facility 
and skin infection after adjustment for confounders (one study), contradictory findings were evident 
for NSP and OST involvement. Specifically, two studies found no significant association between NSP 
use and skin infection; one study showed increased odds of skin infection with past 12-month use of 
NSP services; and one study reported lower odds of skin infection with a greater number of needles 
exchanged at a NSP. For OST, one study showed greater odds of past 12-month skin infection with 
lifetime OST involvement relative to no involvement; another found greater odds of past 12-month 
skin infection with previous OST involvement (but not no OST involvement) relative to current 
involvement; and another showed no significant association.  
***Table 2 approximately here*** 
Infective endocarditis 
There were eight reports assessing prevalence of infective endocarditis (Supplementary Table 3; 
Figure 3). All studies relied on self-reported data.12 6-12 month prevalence was 1.3% (two studies) 
and lifetime prevalence ranged between 0.5% (0.06-1.8%) and 11.8% (4.4-23.9%). One study found 
increased risk of infective endocarditis with older age and longer injecting career; no significant 
association was observed with participant sex.12  
  
***Figure 3 approximately here*** 
Sepsis/septicaemia 
Six reports contributed data on the prevalence of sepsis or septicaemia (Supplementary Table 4). 
Reported 6-12 month prevalence was 1.0% (0.1-3.6%) and 1.3% (0.4-2.9%) in two studies. Lifetime 
prevalence varied between 2.0% (951.7-2.3%) in an Australian sample and 9.8% (3.3-21.4%) in a US 
sample (Figure 4). No studies were identified reporting on the association between the chosen risk 
factors and prevalence of sepsis/septicaemia.  
***Figure 4 approximately here*** 
Bone and joint infections 
Two reports were identified that provided data on bone and joint infections; specifically, septic 
arthritis and osteomyelitis (Supplementary Table 5). Self-reported lifetime prevalence of septic 
arthritis was 1.0% (0.3-2.6%) in an Australian convenience sample5, and 2.0% (0.05-10.4%) in a US 
convenience sample13. In the same reports, lifetime prevalence of osteomyelitis was 0.5% (0.006-
1.8%) 5 and 0%13. No studies were identified reporting on the association between the chosen risk 
factors and prevalence of bone and joint infection. 
Other infections 
Three reports provided data on other infections (Supplementary Table 6). In an Australian sample of 
PWID, Dwyer5 reported 12 month and lifetime prevalence of internal abscess of 1.1% (0.3-2.6%) and 
3.1% (1.6-5.3%), respectively. Nearly one-third (32.8%; 28.2-37.6%) of a convenience sample of 400 
Iranian PWID reported lifetime history of mycotic aneurysm, as confirmed by medical record 
review14. Lifetime prevalence of botulism, necrotizing fasciitis, and tetanus was 3.9% (0.5-13.5%), 
3.9% (0.5-13.5%) and 1.9% (0.005-10.4%) amongst a convenience sample of PWID from the United 
States13. No studies were identified reporting on the association between the chosen risk factors and 
prevalence of other infections.  
  
Thrombosis and emboli 
Nine reports provided data on thrombosis and emboli, including venous thromboembolism, 
thrombophlebitis and deep vein thrombosis. Three studies reported 6-12 month prevalence of 
thrombosis, which ranged between 1.3% (0.4-2.9%) and 9.0% (5.4-13.9%; Figure 5). Lifetime 
prevalence based on six studies (five of which were conducted with Australian convenience samples) 
varied between 3% (2%- 6%) and 27% (14-44%). No studies were identified reporting on the 
association between the chosen risk factors and prevalence of thrombosis and emboli. 
***Figure 5 approximately here*** 
Other and non-specific pathology and dysfunction 
Three reports explored other pathology and dysfunction associated with injecting drug use. Point 
prevalence of chronic venous insufficiency was estimated at between 87.7% (82.4-91.9%) and 93% 
(86.1-97.1%) in the United States among people who inject drugs recruited from methadone 
clinics15, 16 (Supplementary Table 8). A longer history of injecting was strongly associated with more 
severe chronic venous insufficiency.15 Other identified pathology included venous ulcer; hand 
oedema (‘puffy hand syndrome’), and injecting sinus (Supplementary Table 8).  
Risk of bias assessment 
The complete risk of bias assessment is provided in Supplementary Table 1. The majority of included 
reports (24/32; 75%) used non-probability sampling methods such as convenience sampling. 
Response rates were rarely reported, but were above 65% in those studies that noted the response 
rate. IRID were confirmed through clinical assessment or medical record review in 6 reports, with 
the remaining 26 reports relying solely on self-reported history of IRID. Of the latter, nearly half 
(n=12) noted steps that were taken to enhance the validity of self-reports, such as asking 
participants to describe signs and symptoms, or providing participants with clear definitions of 
specific IRID.  
  
Discussion 
 
This review has shown that IRID are a common consequence of injecting drug use. Existing studies 
have found that between 6-32% of people who inject drugs may have experienced injections at 
injecting sites within the previous month. Serious complications of injecting are also a risk, with 
studies finding that 0.5-11.8% may have experienced infective endocarditis and 2-9.8%, septicaemia, 
at some point in their lives. 
Although risk factors for skin infections were not able to be formally meta-analysed, IRID appear 
more common among women than men, and with increasing duration of injecting drug use. 
Conflicting evidence was identified with regards to the impact of harm reduction interventions such 
as needle and syringe programs and opioid substitution therapy on injecting-related injuries and 
diseases; there is a need for research focusing upon the potential impact of injecting risk reduction 
interventions on these consequences of injecting.  
Studies were largely from high-income countries, with participants typically in contact with services 
for people who inject drugs, such as needle and syringe programs and drug treatment clinics. These 
factors should be borne in mind when considering the generalisability of findings to other settings.  
The majority of studies relied on self-reported data on injecting-related injuries and diseases, 
although 12 studies did incorporate measures designed to improve the reliability of self-reports. 
Estimates from studies using those strategies were similar to those relying solely on self-report.  
There was variation between studies in how specific injecting-related injuries and diseases were 
defined. These inconsistencies contribute to difficulties in synthesising data. Other studies reported 
only ‘composite’ variables that combined mild, non-specific problems (e.g. soreness at injecting 
sites) with more severe concerns such as infective endocarditis, obscuring the extent of more serious 
injecting-related injuries and diseases. 
  
Given the wide variation in prevalence estimates between studies, it was not possible to develop 
summary estimates of specific injecting-related injuries and diseases. Further, we were unable to 
formally synthesise data on risk factors for injecting-related injuries and diseases due to a lack of 
data suitable for meta-analysis.  
Implications 
There is an obvious opportunity for research examining correlates and potential risk and protective 
factors for the range of injecting-related injuries and diseases. These studies should adopt a 
consistent list and operationalised definition of specific injecting-related injuries and diseases. An 
alternative to cross-sectional surveys would be to identify population cohorts of people who inject 
drugs via administrative data (e.g. drug treatment registrations) and link these to hospitalisation and 
mortality data. This would allow for generation of incidence and mortality rates and comparisons to 
the general population.  
There is a very high likelihood that not all people who inject drugs will have the same level of risk for 
injecting-related injuries and diseases. Differential risk may arise as a result of the types of drugs 
injected; in the United States, cities dominated by black tar heroin have twice the rate of 
hospitalisations for opiate-related skin and soft tissue infections compared to cities where powder 
heroin predominates.17 People who inject pharmaceuticals may be more likely to experience 
vascular harms given insoluble particles in drug solutions.3 Intensive periods of frequent injecting, 
often associated with methamphetamine and cocaine use, may also impact on risk. These questions 
all require further exploration to assist in targeting prevention activities for injecting-related injuries 
and diseases.  
The data presented here were not able to clearly identify risk or protective effects of harm reduction 
interventions on injecting-related injuries and diseases. Positive associations between needle and 
syringe program attendance or opioid substitution therapy and skin infections at injecting sites may 
  
reflect higher risk injectors making use of these services, or help-seeking following an infection. 
Population-level impacts of needle and syringe programs on injecting-related injuries and diseases 
have been reported elsewhere. In one study, for every eight visits to a needle and syringe program, 
one fewer abscess was treated at community health centres.18 Harm reduction services may also 
offer opportunities to provide treatment for injecting-related injuries and diseases.19 There is a clear 
need to assess the impact of needle and syringe programs and opioid substitution therapy on 
injecting-related injuries and diseases, including cost-benefit analyses.  
Conclusion 
IRID appear to be highly common among people who inject drugs, but there is suggestive evidence 
that prevalence varies widely according to context. There is a need for robust, reliable data on the 
range of injecting-related injuries and diseases among people who inject drugs, particularly in low- 
and middle-income countries. Studies should adopt consistent definitions of injecting-related 
injuries and diseases and ensure transparent reporting of prevalence estimates and risk analyses.  
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Figure 1: Study flow diagram 
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Table 1: Characteristics of included studies 
Study Country Sample size Source of participants Prevalence data  Risk factor data  
Abdali (2005)14 Iran 400 
People who inject drugs in contact with the Isfahan 
Anti-Drug Campaign Center 
Skin infections; infective 
endocarditis; other infections 
Skin infections 
 
Andresz (2006)20 France 66  Methadone clinics N/A 
Other pathology and 
dysfunction 
Axelsson (2014)12 Denmark 206 Supervised drug consumption facilities Infective endocarditis Infective endocarditis 
Barocas (2013)21 USA 553 Needle and syringe programs 
Skin infections; infective 
endocarditis 
N/A 
Binswanger (2000)22 USA 169 Community settings Skin infections Skin infections 
Blondin (2008)23 Canada 1065 Harm reduction services N/A Skin infections 
Buchanan (2006)24 USA 924 Community settings Skin infections N/A 
Conrad (2000)25 Switzerland 1035 Heroin-assisted treatment sample Skin infections N/A 
Coull (2014)26 Scotland 200 
Needle and syringe programs and methadone 
clinics 
Skin infections N/A 
Darke (2001)27 Australia 200 
Needle and syringe programs and community 
settings 
Skin infections; thrombosis and 
emboli; Sepsis 
N/A 
Dwyer (2009)5 Australia 393 
Needle and syringe programs and community 
settings 
Skin infections; infective 
endocarditis; sepsis; bone and 
joint infections; other infections; 
thrombosis and emboli; other 
pathology and dysfunction 
N/A 
Fink (2013)28 USA 858 
Needle and syringe programs and community 
settings 
Skin infections Skin infections 
Hope (2008)29 England 1058 
Drop-in centres, needle and syringe programs and 
community settings 
Skin infections Skin infections 
Hope (2010)11 England 5209 
Needle and syringe programs, drug treatment 
providers and other services for people who inject 
drugs 
Skin infections Skin infections 
Hope (2014)30 England 855 
Respondent-driven sampling; initial recruits 
identified using street outreach and key informants 
Skin infections Skin infections 
Hope (2015)31 England 855 
Respondent-driven sampling; initial recruits 
identified using street outreach and key informants 
Skin infections; infective 
endocarditis; sepsis 
Skin infections 
Hope (2015)32 England 855 
Respondent-driven sampling; initial recruits 
identified using street outreach and key informants 
Thrombosis and emboli N/A 
  
Study Country Sample size Source of participants Prevalence data  Risk factor data  
Jenkinson (2005)33 Australia 156 
Needle and syringe programs and community 
settings 
Skin infections; thrombosis and 
emboli 
N/A 
Johnson (2013)34 USA 81 Needle and syringe program Skin infections N/A 
Lloyd-Smith (2005)35 Canada 1585 Unclear Skin infections Skin infections 
Lloyd-Smith (2008)36 Canada 1065 Supervised injecting facility Skin infections Skin infections 
Maloney (2010)37 Ireland 70 Methadone clinics Skin infections N/A 
Phillips (2010)13 USA 51 
Drop-in centre, drug treatment centre and 
community settings 
Skin infections; infective 
endocarditis; sepsis; bone and 
joint infections; other pathology 
and dysfunction 
Skin infections 
Pieper (2001)15 USA 204 Methadone clinics Other pathology and dysfunction 
Other pathology and 
dysfunction 
Pieper (2003)16 USA 100 Medical clinic and methadone clinic Other pathology and dysfunction N/A 
Pollini (2010)38 Mexico 623 
Respondent-driven sampling; initial recruits were 
selected to be diverse in age, sex and 
neighbourhood of residence 
Skin infections Skin infections 
Robertson (2010)39 Mexico 1056 
Respondent-driven sampling; initial recruits were 
selected to be diverse in age, sex and 
neighbourhood of residence 
Skin infections N/A 
Salmon (2009)1 Australia 9552 Supervised injecting facility 
Skin infections; infective 
endocarditis; sepsis; thrombosis 
and emboli 
N/A 
Tomolillo (2007)18 USA 62 Former PWID attending a 12-step meeting N/A Skin infections 
Topp (2008)40 Australia 1961 Needle and syringe programs 
Skin infections; infective 
endocarditis; sepsis; thrombosis 
and emboli 
N/A 
Williams (2006)41 England 37 Drug treatment clinics Thrombosis and emboli N/A 
Yen (2015)42 Taiwan 802 Methadone clInics Skin infections N/A 
  
Figure 2: Prevalence of skin infections at injecting site in people who inject drugs, by prevalence 
period 
 
 
  
Table 2: Associations between skin infections at injection sites and demographic factors, injecting 
characteristics, and harm reduction service use among people who inject drugs 
Risk factor/ 
prevalence 
period 
Study Risk factor level Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Sex 
Current-1 month Lloyd-Smith, 2008 
Male 
Female 
- 
1.9 (1.4, 2.6) 
- 
1.7 (1.2, 2.4) 
6-12 months Blondin, 2008 
Male 
Female 
- 
Not reported 
- 
0.7 (0.5, 1.0) 
6-12 months Fink, 2013 
Male 
Female 
- 
1.7 (1.3, 2.3) 
- 
1.4 (1.0, 2.0) 
6-12 months Hope, 2008 
Male 
Female 
- 
1.4 (1.1, 1.9) 
- 
1.7 (1.2, 2.4) 
6-12 months Hope, 2010 
Male 
Female 
- 
1.3 (1.1, 1.5) 
- 
1.4 (1.3, 1.6) 
6-12 months Hope, 2015 
No data reported; “An abscess was not associated with 
gender” 
6-12 months Lloyd-Smith, 2005 
Male 
Female 
- 
2.4 (1.9, 3.0) 
- 
1.7 (1.4, 2.4) 
6-12 months Pollini, 2010 
Male 
Female 
- 
2.3 (1.4, 3.6) 
Not reported 
6-12 months Safaeian, 2000 
Male 
Female 
- 
2.2 (1.6, 2.8) 
- 
2.0 (1.5, 2.8) 
Age 
Current-1 month Lloyd-Smith, 2008 per year increase 1.0 (1.0, 1.0) Not reported 
6-12 months Blondin, 2008 No data; report states no significant association 
6-12 months Fink, 2013 
<30 years 
30-39 years 
40-49 years 
50+ years 
 
Not reported 
 
- 
0.7 (0.3, 1.6) 
1.1 (0.5, 2.2) 
1.0 (0.5, 2.1) 
6-12 months Hope, 2008 
<=24 years 
25-29 years 
30-34 years 
35+ years 
- 
1.8 (1.2, 2.7) 
2.1 (1.4, 3.2) 
1.9 (1.3, 2.9) 
- 
1.6 (1.0, 2.6) 
2.0 (1.3, 3.2) 
1.9 (1.2, 3.0) 
6-12 months Hope, 2010 
<30 years 
30+ years 
- 
1.3 (1.2, 1.5) 
Not reported 
6-12 months Hope, 2015 
<30 years 
30+ years 
- 
1.7 (1.2, 2.4) 
Not reported 
6-12 months Lloyd-Smith, 2005 No data; report states significant association 
6-12 months Phillips, 2010 per year increase 1.0 (0.9, 1.0) Not reported 
6-12 months Pollini, 2010 
Median age of those with/without abscess: 39 years/37 years, 
p=0.14 
6-12 months Safaeian, 2000 
<34 years 
>34 years 
- 
1.4 (1.0, 1.8) 
Not reported 
Lifetime Abdali, 2005 No data; report states no significant association 
Duration of injecting 
Current-1 month Binswanger, 2000 
<10 years 
10+ years 
- 
0.5 (0.2, 1.2) 
Not reported 
Current-1 month Hope, 2014 No data; report states no significant association 
6-12 months Fink, 2013 
<10 years 
10+ years 
- 
1.6 (1.0, 2.4) 
Not reported 
6-12 months Hope, 2008 
<10 years 
10+ years 
- 
1.3 (1.0, 1.7) 
Not reported 
  
Risk factor/ 
prevalence 
period 
Study Risk factor level Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
6-12 months Hope, 2010 
<5 years 
5-9 years 
10-14 years 
15+ years 
Not reported 
- 
1.3 (1.1, 1.5) 
1.4 (1.2, 1.6) 
1.7 (1.5,2.1) 
6-12 months Hope, 2015 
<10 years 
10+ years 
- 
1.9 (1.3, 2.7) 
Not reported 
Lifetime Abdali, 2005 “p<.001” but direction of association not reported 
Injection frequency 
Current-1 month Hope, 2014 
N days injected 
past 28 days: 
<14 days 
14-27 days 
28 days 
Not reported 
 
 
- 
2.5 (1.0, 6.6) 
4.3 (1.8, 10.0) 
6-12 months Hope, 2008 
N days injected 
past 28 days: 
<14 days 
14-27 days 
28 days 
 
 
- 
2.0 (1.3, 3.1) 
1.9 (1.3, 2.7) 
 
 
- 
1.8 (1.2, 2.9) 
1.5 (1.0, 2.3) 
6-12 months Hope, 2010 
N days injected 
past 28 days: 
<14 days 
14-27 days 
28 days 
Not reported 
 
 
- 
1.1 (0.9, 1.3) 
1.2 (1.0, 1.5) 
6-12 months Phillips, 2010 
“Frequency of 
injecting” (not 
further defined) 
14.0 (0.7, 2.4) Not reported 
6-12 months Pollini, 2010 
Past 6 months: 
< Daily injection 
Daily injection 
 
- 
1.3 (0.7, 2.4) 
Not reported 
6-12 months Safaeian, 2000 
Past 6 months: 
< Daily injection 
Daily injection 
 
- 
2.3 (1.4, 2.3)* 
 
- 
2.5 (1.9, 3.3) 
Use of opioid substitution therapy 
6-12 months Hope, 2008 
Currently 
Previously  
Never 
- 
1.6 (1.2, 2.2) 
0.6 (0.4, 0.9) 
- 
1.7 (1.3, 2.4) 
0.9 (0.5, 1.3) 
6-12 months Hope, 2010 
Never 
Ever 
- 
1.4 (1.2, 1.7) 
Not reported 
6-12 months Lloyd-Smith, 2005 No data; report states no significant association 
 Use of needle and syringe programs 
Current-1 month Binswanger, 2000 
Used NSP past 30 
days: 
No 
Yes 
 
 
- 
1.0 (0.4, 2.2) 
Not reported 
6-12 months Fink, 2013 
“NSP client”: 
No 
Yes 
 
- 
1.0 (0.8, 1.4) 
 
- 
0.9 (0.7, 1.3) 
6-12 months Hope, 2010 
Used NSP past 
year: 
No 
Yes 
 
 
- 
1.6 (1.3, 2.0) 
 
 
- 
1.7 (1.4, 2.0) 
Not reported Tomolillo, 2007 
“Self-reports of greater numbers of needles exchanges were 
significantly related to lower occurrences of abscesses” 
  
Risk factor/ 
prevalence 
period 
Study Risk factor level Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Use of supervised injecting facility  
Current-1 month Lloyd-Smith, 2008 
Inject at SIF:  
Not always 
Always 
 
- 
0.5 (0.2, 0.9) 
 
- 
0.6 (0.3, 1.2) 
Unadjusted ORs calculated from published numerators and denominators, if available, or as published if not 
available. Adjusted ORs are as published. * Unadjusted OR is reported as published; no raw data available to 
recalculate.
  
Figure 3: Prevalence of infective endocarditis in people who inject drugs, by prevalence period.  
 
 
  
Figure 4: Prevalence of sepsis/septicaemia amongst people who regularly inject drugs, by prevalence period 
 
  
Figure 5: Prevalence of thrombosis and emboli in people who inject drugs, by prevalence period 
 
Note: DVT, deep vein thrombosis 
